» Articles » PMID: 38753726

Antiretroviral Therapy Suppresses RNA -Methyladenosine Modification in Peripheral Blood Mononuclear Cells from HIV-1-Infected Individuals

Overview
Publisher Mary Ann Liebert
Date 2024 May 16
PMID 38753726
Authors
Affiliations
Soon will be listed here.
Abstract

RNA -methyladenosine (mA) modification is important for regulating gene expression and innate immune responses to viral infection. HIV-1 infection induces a significant increase in mA modification of cellular RNA; however, whether mA levels of cellular RNA are affected by HIV-1 replication or by antiretroviral therapy (ART) in infected individuals remains unknown. Using dot blot or enzyme-linked immunosorbent assay, we measured RNA mA levels of peripheral blood mononuclear cells (PBMCs) from healthy donors or HIV-1-infected individuals with or without ART. Using a reverse transcription-quantitative polymerase chain reaction array, we quantified expression levels of 84 type-I interferon (IFN-I)-responsive genes in PBMCs from some individuals of these three groups. RNA mA levels in PBMCs from HIV-1 viremic patients ( = 10) were significantly higher ( ≤ .0001) compared with ART-treated individuals ( = 22) or 1.5-fold higher compared with healthy donors ( = 14). However, the increase in RNA mA levels did not correlate with changes in the expression of 10 mA-regulatory genes. We found significant upregulation and downregulation in the expression of several IFN-I-responsive genes from HIV-1 viremic patients ( = 4) and ART-treated patients ( = 6) compared with healthy donors ( = 5), respectively. Our results suggest that post-transcriptional mA modification may contribute to the regulation of IFN-I-responsive gene expression during HIV-1 infection and ART.

Citing Articles

Single-base mA epitranscriptomics reveals novel HIV-1 host interaction targets in primary CD4 T cells.

Huang S, Zhao Y, Phillips S, Wilms B, He C, Wu L bioRxiv. 2025; .

PMID: 39803509 PMC: 11722377. DOI: 10.1101/2024.12.31.630958.


Epitranscriptomic mA modifications during reactivation of HIV-1 latency in CD4 T cells.

Mishra T, Phillips S, Zhao Y, Wilms B, He C, Wu L mBio. 2024; 15(11):e0221424.

PMID: 39373537 PMC: 11559067. DOI: 10.1128/mbio.02214-24.

References
1.
Huang W, Chen T, Fang K, Zeng Z, Ye H, Chen Y . N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021; 14(1):117. PMC: 8313886. DOI: 10.1186/s13045-021-01129-8. View

2.
Pereira-Montecinos C, Valiente-Echeverria F, Soto-Rifo R . Epitranscriptomic regulation of viral replication. Biochim Biophys Acta Gene Regul Mech. 2017; 1860(4):460-471. DOI: 10.1016/j.bbagrm.2017.02.002. View

3.
Yang Y, Hsu P, Chen Y, Yang Y . Dynamic transcriptomic mA decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018; 28(6):616-624. PMC: 5993786. DOI: 10.1038/s41422-018-0040-8. View

4.
Halvas E, Joseph K, Brandt L, Guo S, Sobolewski M, Jacobs J . HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. J Clin Invest. 2020; 130(11):5847-5857. PMC: 7598056. DOI: 10.1172/JCI138099. View

5.
Board N, Moskovljevic M, Wu F, Siliciano R, Siliciano J . Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol. 2021; 22(8):499-512. DOI: 10.1038/s41577-021-00649-1. View